CHAMPIONS ONCOLOGY, INC.

In this section, information is discussed with respect to "named executive officers" ("NEOs"). As defined by the SEC regulations applicable to the Company, NEOs include all individuals who served as the Company’s principal executive officer (PEO) during the fiscal year ended April 30, 2026, the Company’s three most highly compensated executive officers whose total compensation for the fiscal year ended April 30, 2026 exceeded $100,000 (other than the principal executive officer) and who were serving in such capacities on April 30, 2025, and up to two additional individuals for whom disclosure would have been provided as the three most highly compensated executive officers but for the fact that they were not serving as executive officers on April 30, 2026. The Company’s PEO at April 30, 2026 was Mr. Brainin (since August 2026) and the Company’s other most highly compensated executive officer at April 30, 2026 was Mr. Miller. Mr. Morris was PEO and CEO in fiscal 2025 and for a portion of fiscal 2026 before transitioning roles in the Company. During fiscal 2025, the other two most highly compensated officers were Mr. Miller and Mr. Davis.